Dapagliflozin reduced left ventricular mass index early into treatment in patients with nondialysis-dependent CKD, regardless of disease etiology and cardiovascular history. Dapagliflozin reduces left ...

Association of sodium-glucose co-transporter-2 inhibitors with cardiac outcomes and mortality in cancer patients: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ...

Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...